Martin Møller works with strategy, transformation and innovation in pharmaceuticals and medical products companies and other industries where innovation plays a central role.
Recent project highlights include the creation of global launch plans that addressed supply, regulatory, and commercial issues for a primary-care blockbuster; support to a global R&D strategy and transformation program for a major pharma company; identification of strategic and operational opportunities in a small-molecule-focused R&D organization; development of a research strategy to help a client enter selected new disease areas; and the design of a new approach to cross-functional management of R&D projects.
Published work
“Fast-forward: Will the speed of COVID-19 vaccine development reset industry norms?,” McKinsey & Company, May 2021
“Unlocking the power of translational medicine,” McKinsey & Company, February 2020
“Big, bigger, biggest data: CTO Peter Løngreen on Denmark’s national genome project,” McKinsey & Company, February 2020
“The fragmentation of biopharmaceutical innovation,” Nature Reviews Drug Discovery, March 2019
“Trends in clinical success rates,” Nature Reviews Drug Discovery, May 2016
“Improving R&D productivity,” Nature Reviews Drug Discovery, June 2015
“Outlook for the next 5 years in drug innovation,” Nature Reviews Drug Discovery, June 2012
“Escaping the sword of Damocles: Toward a new future for pharmaceutical R&D,” (PDF–1.76 MB), McKinsey, 2012
Education
University of Copenhagen
MA in comparative literature
2000